Literature DB >> 23566963

The changing epidemic of lung cancer and occupational and environmental risk factors.

Carolyn Dresler1.   

Abstract

The epidemiology of lung cancer continues to evolve. Since the invention of a machine that could rapidly manufacture cigarettes in the 1880s, tobacco smoking has progressively been the major causative agent for the lung cancer epidemic. Until tobacco inhalation is ceased, globally, there will continue to be readily preventable lung cancers. Because cigarettes and other products the tobacco industry develops or modifies for inhalation are continually changing, the types of lung cancer could continue to change. There are other causes of lung cancer in people who never smoke, which include environmental and occupational. Enough is now known to implement strong policies that could eliminate most lung cancers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566963     DOI: 10.1016/j.thorsurg.2013.01.015

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  12 in total

1.  MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes.

Authors:  Anna A Shvedova; Elena R Kisin; Naveena Yanamala; Alexey V Tkach; Dmitriy W Gutkin; Alexander Star; Galina V Shurin; Valerian E Kagan; Michael R Shurin
Journal:  Cancer Res       Date:  2015-03-05       Impact factor: 12.701

2.  The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth.

Authors:  L Li; S Li; T Cai; H Wang; X Xie; Z Liu; Y Zhang
Journal:  Gene Ther       Date:  2015-08-17       Impact factor: 5.250

Review 3.  Lung cancer in women: an overview with special focus on Spanish women.

Authors:  J Remon; E Molina-Montes; M Majem; P Lianes; D Isla; P Garrido; E Felip; N Viñolas; J de Castro; A Artal; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2013-11-26       Impact factor: 3.405

4.  Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.

Authors:  Oscar Arrieta; Roger Humberto Quintana-Carrillo; Gabriel Ahumada-Curiel; Jose Francisco Corona-Cruz; Elma Correa-Acevedo; Juan Zinser-Sierra; Dolores de la Mata-Moya; Alejandro Mohar-Betancourt; Vicente Morales-Oyarvide; Luz Myriam Reynales-Shigematsu
Journal:  Tob Induc Dis       Date:  2015-02-04       Impact factor: 2.600

5.  Alpha5 Nicotinic Acetylcholine Receptor Contributes to Nicotine-Induced Lung Cancer Development and Progression.

Authors:  Hai-Ji Sun; Yan-Fei Jia; Xiao-Li Ma
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

6.  Estimated costs of advanced lung cancer care in a public reference hospital.

Authors:  Renata Erthal Knust; Margareth Crisóstomo Portela; Claudia Cristina de Aguiar Pereira; Guilherme Bastos Fortes
Journal:  Rev Saude Publica       Date:  2017-08-17       Impact factor: 2.106

7.  Role of α7-nicotinic acetylcholine receptor in nicotine-induced invasion and epithelial-to-mesenchymal transition in human non-small cell lung cancer cells.

Authors:  Chun Zhang; Xu-Ping Ding; Qing-Nan Zhao; Xin-Jie Yang; Shi-Min An; Hao Wang; Lu Xu; Liang Zhu; Hong-Zhuan Chen
Journal:  Oncotarget       Date:  2016-09-13

8.  XAB2 tagSNPs contribute to non-small cell lung cancer susceptibility in Chinese population.

Authors:  Na Pei; Lei Cao; Yingwen Liu; Jing Wu; Qinqin Song; Zhi Zhang; Juxiang Yuan; Xuemei Zhang
Journal:  BMC Cancer       Date:  2015-07-31       Impact factor: 4.430

9.  Characteristics and prognostic factors for pain management in 152 patients with lung cancer.

Authors:  Lei Shi; Yumei Liu; Hua He; Cong Wang; Hongwei Li; Nanya Wang
Journal:  Patient Prefer Adherence       Date:  2016-04-15       Impact factor: 2.711

10.  "Factors associated with non-small cell lung cancer treatment costs in a Brazilian public hospital".

Authors:  Carla de Barros Reis; Renata Erthal Knust; Claudia Cristina de Aguiar Pereira; Margareth Crisóstomo Portela
Journal:  BMC Health Serv Res       Date:  2018-02-17       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.